HIGHLY SELECTIVE ACTIVITY OF MDM2 INHIBITOR RG7112 AGAINST MDM2-AMPLIFIED/TP53 WILD-TYPE GLIOBLASTOMAS

被引：0
|
作者：
Verreault, Maite [1 ,2 ,3 ,4 ]
Levasseur, Camille [1 ,2 ,3 ,4 ]
Schmitt, Charlotte [1 ,2 ,3 ,4 ]
Guehennec, Jeremy [1 ,2 ,3 ,4 ]
Labussiere, Marianne [1 ,2 ,3 ,4 ]
Marie, Yannick [1 ,2 ,3 ,4 ]
Haidar, Sam [5 ,6 ]
Mokhtari, Karima [1 ,2 ,3 ,4 ,7 ]
Hoang-Xuan, Khe [1 ,2 ,3 ,4 ,7 ]
Sanson, Marc [1 ,2 ,3 ,4 ,7 ]
Ligon, Keith [5 ,6 ]
Delattre, Jean-Yves [1 ,2 ,3 ,4 ,7 ]
Idbaih, Ahmed [1 ,2 ,3 ,4 ,7 ]
机构：
[1] INSERM, U1127, F-7501 Paris, France
[2] CNRS, UMR 7225, F-75013 Paris, France
[3] Univ Paris 06, Sorbonne Univ, UMR S 1127, F-75013 Paris, France
[4] ICM, F-750133 Paris, France
[5] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA
[6] Brigham & Womens Hosp & Childrens, Div Neuropathol, Dept Pathol, Boston, MA USA
[7] Hop La Pitie Salpetriere, AP HP, Serv Neuropathol R Escourolle, Serv Neurol, F-75013 Paris, France
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou255.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ET-62
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
    Verreault, Maite
    Schmitt, Charlotte
    Goldwirt, Lauriane
    Pelton, Kristine
    Haidar, Samer
    Levasseur, Camille
    Guehennec, Jeremy
    Knoff, David
    Labussiere, Marianne
    Marie, Yannick
    Ligon, Azra H.
    Mokhtari, Karima
    Khe Hoang-Xuan
    Sanson, Marc
    Alexander, Brian M.
    Wen, Patrick Y.
    Delattre, Jean-Yves
    Ligon, Keith L.
    Idbaih, Ahmed
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1185 - 1196
  • [2] Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas (vol 22, pg 1185, 2016)
    Verreault, M.
    Schmitt, C.
    Goldwirt, L.
    Pelton, K.
    Haidar, S.
    Levasseur, C.
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2313 - 2313
  • [3] Antitumor activity of the MDM2 antagonist, RG7112
    Tovar, Christian
    Filipovic, Zoran
    Thompson, Thelma
    Higgins, Brian
    Kolinsky, Kenneth
    Packman, Kathryn
    Deo, Dayanand
    Vu, Binh
    Graves, Bradford
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2012, 72
  • [4] Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
    Iancu-Rubin, Camelia
    Mosoyan, Goar
    Glenn, Kelli
    Gordon, Ronald E.
    Nichols, Gwen L.
    Hoffman, Ronald
    EXPERIMENTAL HEMATOLOGY, 2014, 42 (02) : 137 - 145
  • [5] Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
    Vu, Binh
    Wovkulich, Peter
    Pizzolato, Giacomo
    Lovey, Allen
    Ding, Qingjie
    Jiang, Nan
    Liu, Jin-Jun
    Zhao, Chunlin
    Glenn, Kelli
    Wen, Yang
    Tovar, Christian
    Packman, Kathryn
    Vassilev, Lyubomir
    Graves, Bradford
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (05): : 466 - 469
  • [6] Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
    Ray-Coquard, Isabelle
    Blay, Jean-Yves
    Italiano, Antoine
    Le Cesne, Axel
    Penel, Nicolas
    Zhi, Jianguo
    Heil, Florian
    Rueger, Ruediger
    Graves, Bradford
    Ding, Meichun
    Geho, David
    Middleton, Steven A.
    Vassilev, Lyubomir T.
    Nichols, Gwen L.
    Binh Nguyen Bui
    LANCET ONCOLOGY, 2012, 13 (11): : 1133 - 1140
  • [7] Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program
    Carol, Hernan
    Reynolds, C. Patrick
    Kang, Min H.
    Keir, Stephen T.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Billups, Catherine A.
    Geier, Brian
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (04) : 633 - 641
  • [8] A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)
    Dumbrava, Ecaterina Elena
    Hanna, Glenn J.
    Cote, Gregory Michael
    Stinchcombe, Tom
    Johnson, Melissa Lynne
    Chen, Christopher
    Devarakonda, Siddhartha
    Shah, Naisargee
    Xu, Feng
    Doebele, Robert Charles
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Milademetan is a highly potent MDM2 inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC)
    Ananthapadmanabhan, Varsha
    Frost, Thomas C.
    Soroko, Kara M.
    Knott, Aine
    Magliozzi, Brianna
    Gokhale, Prafulla C.
    Tirunagaru, Vijaya
    Doebele, Robert C.
    DeCaprio, James A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (10) : 2837 - 2837
  • [10] Brain distribution of the MDM2 inhibitor, RG7112: Single dose escalation and repeated doses studies.
    Goldwirt, Lauriane
    Verreault, Maite
    Levasseur, Camille
    Schmitt, Charlotte
    Guehennec, Jeremy
    Labussiere, Marianne
    Haidar, Sam
    Mokhtari, Karima
    Mourah, Samia
    Hoang-Xuan, Khe
    Sanson, Marc
    Wen, Patrick Y.
    Ligon, Keith L.
    Delattre, Jean-Yves
    Idbaih, Ahmed
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345